Repligen (RGEN)
(Delayed Data from NSDQ)
$146.70 USD
+2.21 (1.53%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $146.85 +0.15 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$146.70 USD
+2.21 (1.53%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $146.85 +0.15 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H
by Zacks Equity Research
Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.
Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations
by Zacks Equity Research
Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo
by Zacks Equity Research
Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
by Zacks Equity Research
Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.
Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate
by Zacks Equity Research
Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.
Horizon (HZNP) Begins Phase II Study for Lupus Candidate
by Zacks Equity Research
Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.
Exelixis (EXEL) Down on Data from Ongoing Liver Cancer Study
by Zacks Equity Research
Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.
Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma
by Zacks Equity Research
Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.
BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism
by Zacks Equity Research
Biomarin Pharmaceutical (BMRN) receives positive recommendation from Europe's CHMP for vosoritide to treat achondroplasia in children.
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.
Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA
by Zacks Equity Research
The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.
Entera (ENTX) Up on Positive Results From Osteoporosis Drug
by Zacks Equity Research
Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.
Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment
by Zacks Equity Research
Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
by Zacks Equity Research
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.
Bristol Myers' (BMY) Onureg Gets European Commission Approval
by Zacks Equity Research
Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.
Geron (GERN) Soars on Imetelstat Data for Myelofibrosis
by Zacks Equity Research
Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.
Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate
by Zacks Equity Research
Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate
by Zacks Equity Research
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM
by Zacks Equity Research
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.